Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Global $94.6 Bn Contract Pharmaceutical Manufacturing Market, 2022 | ||
| By: PR Newswire Association LLC. - 22 Sep 2017 | Back to overview list |
|
DUBLIN, September 22, 2017 /PRNewswire/ -- The "Global Contract Pharmaceutical Manufacturing Market - By Dose Formulation Type, Region - Market Size, Demand Forecasts, Industry Trends and Updates(2016-2022)" report has been added to Research and Markets' offering. Global Contract Pharmaceutical manufacturing market is estimated to reach $94.63 billion by 2022 from $65.55 billion in 2016, at a CAGR of 6.31% for the forecasted period. Solid dose formulation constituted 42% of the market in 2016. Contract Pharmaceutical manufacturing is a process of outsourcing certain production activities to third party manufacturers. These manufacturers are given the chemical formulation by pharma companies. This type of contract manufacturing is witnessing a rising trend as more and more pharma companies are trying to focus more on R&D of drugs rather than getting involved in the production of drugs in order to gain competitive advantage in the business. This industry is classified into API manufacturing and Finished Dosage formulation(FDF) manufacturing. FDF formulation is further divided into solid dose formulation, liquid dose formulation and injectable dose formulation. North America holds the major share in Global Contract Pharmaceutical manufacturing market. Asia-Pacific-especially India-is the fastest growing market. US, Canada, China, India, Japan and Australia are main countries operating in this industry. Increasing consumption of medicines around the globe, aging population, increasing rate of approvals, adoption of novel manufacturing technologies, increasing demand for generic drugs, robust pipeline of drugs and increasing number of patent expires are some of the factors fuelling the growth of this industry.Availability of skilled workforce and lower labour cost are some of the factors propelling the rapid growth of Asia-Pacific market.Increasing complexity of clinical trials, lack of in-house laboratory capacity are some of the challenges in this industry. Major companies operating in Contract Pharmaceutical manufacturing industry include HAUPT Pharma AG, Abbott Laboratories,Pfizer,Catalent Pharma Solutions, Althea Technologies and Nipro Corp.Several firms have acquired contract service providers to achieve vertical integration. Mergers and Acquisitions are also one of the key strategies being adopted by various companies.Pharma companies are also turning to contract packaging companies for novel packaging solutions. Also there is a transition from vertically integration to an ecosystem of interconnected suppliers by major players. Key Topics Covered: 1. Research Methodology 2. Executive Summary 3. Market Overview
4. Market Dynamics
5. Global Contract Pharmaceutical Manufacturing market Segmentation, Forecasts and Trends - By Revenue
7. By Region
8. Vendor Market Share Analysis
10. Industry Structure
11. Global Pharmaceutical Contract Manufacturing market - Road Ahead
For more information about this report visit https://www.researchandmarkets.com/research/m3ljmn/global_contract Media Contact: Laura Wood, Senior Manager
View original content:http://www.prnewswire.com/news-releases/global-946-bn-contract-pharmaceutical-manufacturing-market-2022-300524287.html SOURCE Research and Markets 
|
||
|
||
 | Back to overview list | |